Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ibalizumab.

Robert L Bettiker1, David E Koren2, Jeffrey M Jacobson1,3,4

  • 1Department of Medicine.

Current Opinion in HIV and AIDS
|May 11, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic risk prediction of type 2 diabetes in people living with and without HIV.

Scientific reports·2026
Same author

Interleukin-2 is a potent latency reversal agent in people with treated HIV-1.

Science advances·2025
Same author

Age modifies the association between sex and the plasma inflammatory proteome in treated HIV.

The Journal of clinical investigation·2025
Same author

Lenacapavir: A Twice-Yearly Injectable for HIV Preexposure Prophylaxis.

The Annals of pharmacotherapy·2025
Same author

Sex differences in HIV-1 reservoir cell selection are linked to altered innate immune profiles.

Science translational medicine·2025
Same author

Burden of Chronic Health Conditions Among People With HIV and Common Non-AIDS-Defining Cancers.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same journal

Implications of HIV persistence and pathogenesis in microglia.

Current opinion in HIV and AIDS·2026
Same journal

Paediatric HIV cure section in Current Opinion in HIV and AIDS.

Current opinion in HIV and AIDS·2026
Same journal

Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control.

Current opinion in HIV and AIDS·2026
Same journal

Natural killer cells in pediatric HIV cure strategies: from viral control to immunotherapeutics.

Current opinion in HIV and AIDS·2026
Same journal

Nonhuman primate models of HIV reveal reservoir dynamics and promising interventions.

Current opinion in HIV and AIDS·2026
Same journal

Impact of sex differences in adult and paediatric HIV-1 cure.

Current opinion in HIV and AIDS·2026
See all related articles

Ibalizumab, a new HIV-1 treatment, effectively reduces viral load in patients with multidrug resistance. This parenteral CD4 post-attachment inhibitor shows promise as a safe and effective option for difficult-to-treat HIV-1 infections.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Multiclass resistant HIV-1 necessitates novel antiretroviral agents.
  • Ibalizumab offers a unique mechanism of action as a parenteral CD4 post-attachment inhibitor.

Purpose of the Study:

  • To review the efficacy and safety of ibalizumab in treating HIV-1.
  • To highlight ibalizumab's role in combination antiretroviral therapy for resistant HIV-1.

Main Methods:

  • Phase III clinical trial involving HIV-infected participants with multiclass antiretroviral drug resistance.
  • Intravenous administration of ibalizumab followed by an optimized background antiretroviral regimen.

Main Results:

  • 83% of participants achieved >0.5 log decline in plasma HIV-1 RNA at 1 week.

Related Experiment Videos

  • 43% achieved plasma HIV-1 RNA <50 copies/ml at 24 weeks with combination therapy.
  • Ibalizumab demonstrated a favorable safety profile with uncommon, low-grade adverse effects.

    • Conclusions:

    • Ibalizumab is a safe and effective treatment for HIV-1 infection, particularly for multidrug-resistant cases.
    • It is approved as Trogarzo for use in combination antiretroviral therapy.
    • Ongoing development aims to enhance ibalizumab's pharmacokinetic profile and broaden its activity.